Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GNA15 | P30679 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15239455 | 1.00 | FFAR1 (0.54) | FFAR1LMNAL3MBTL1NR1H4RAB9A | |
| SCHEMBL437238 | 1.00 | FFAR1 (0.54) | FFAR1LMNAL3MBTL1NR1H4RAB9A | |
| SCHEMBL15239473 | 0.94 | FFAR1 (0.55) | FFAR1RAB9ASMN1; SMN2GNA15NPC1 | |
| SCHEMBL15239474 | 0.94 | FFAR1 (0.55) | FFAR1RAB9ASMN1; SMN2GNA15NPC1 | |
| SCHEMBL15239589 | 0.92 | FFAR1 (0.56) | FFAR1L3MBTL1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL10259320 | 0.92 | FFAR1 (0.56) | FFAR1L3MBTL1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL22668104 | 0.90 | FFAR1 (0.55) | FFAR1L3MBTL1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL14886948 | 0.90 | FFAR1 (0.55) | FFAR1L3MBTL1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL433639 | 0.90 | FFAR1 (0.61) | FFAR1GNA15 | |
| SCHEMBL433638 | 0.90 | FFAR1 (0.61) | FFAR1GNA15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| EP-2595952-A1 | AGONISTS OF GPR40 | Connexios Life Sciences Pvt. Ltd. (IN) | 2013-05-29 | — | — | EP | disclosed |
| WO-2013057743-A1 | PROCESS FOR THE PREPARATION OF AN ARYL OXIME AND SALTS THEREOF | CONNEXIOS LIFE SCIENCES PVT. LTD (IN) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237571-A1 | AGONISTS OF GPR40 | GPR65, GPR55, GPR68 | FFAR1 24/4885LMNA 3516/4885L3MBTL1 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.